First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups

被引：0
|
作者：
Wu, Y. [1 ,2 ]
Cheng, Y. [3 ]
Zhou, X. [4 ]
Lee, K. H. [5 ]
Nakagawa, K. [6 ]
Niho, S. [7 ]
Tsuji, F. [8 ]
Rosell, R. [9 ]
Corral, J. [10 ]
Migliorino, M. R. [11 ]
Pluzanski, A. [12 ]
Linke, R. [13 ]
Sbar, E. [14 ]
Wang, T. [15 ]
Zhang, H. [16 ]
Mok, T. [17 ]
机构：
[1] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Jilin Prov Canc Hosp, Changchun, Jilin, Peoples R China
[4] Third Mil Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[5] Chungbuk Natl Univ Hosp, Chungcheongbuk Do, South Korea
[6] Kindai Univ Hosp, Osaka, Japan
[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[8] Sfj Pharma Japan KK, Osaka, Japan
[9] Germans Trias I Pujol Hlth Sci Inst, Catalan Inst Oncol, Barcelona, Spain
[10] Hosp Univ Virgen Del Rocio, Seville, Spain
[11] San Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy
[12] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland
[13] Sfj Pharmaceut Grp, Pleasanton, CA USA
[14] Pfizer Oncol, Collegeville, PA USA
[15] Pfizer Oncol, Groton, CT USA
[16] Pfizer Oncol, Shanghai, Peoples R China
[17] Chinese Univ Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
EGFR mutations; Dacomitinib; advanced non-small-cell lung cancer;
D O I：
10.1016/j.jtho.2017.09.347
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA 05.01
引用
收藏
页码：S1754 / S1754
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA
    Yu, Y.
    Luan, L.
    Zhu, F.
    Dong, P.
    Li, L.
    Lin, Y.
    Lu, S.
    VALUE IN HEALTH, 2019, 22 : S467 - S468
  • [2] First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Sequist, Lecia V.
    Martins, Renato G.
    Spigel, David
    Grunberg, Steven M.
    Spira, Alexander
    Jaenne, Pasi A.
    Joshi, Victoria A.
    McCollum, David
    Evans, Tracey L.
    Muzikansky, Alona
    Kuhlmann, Georgiana L.
    Han, Moon
    Goldberg, Jonathan S.
    Settleman, Jeffrey
    Iafrate, A. John
    Engelman, Jeffrey A.
    Haber, Daniel A.
    Johnson, Bruce E.
    Lynch, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2442 - 2449
  • [3] Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China
    Xu, Xinglu
    Fang, Nan
    Li, Huanan
    Liu, Yanyan
    Yang, Fan
    Li, Xin
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (09)
  • [4] Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
    Reungwetwattana, Thanyanan
    Rohatgi, Nitesh
    Mok, Tony S.
    Prabhash, Kumar
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 161 - 171
  • [5] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [6] Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
    Pluzanski, A.
    Wu, Y.
    Cheng, Y.
    Zhou, X.
    Migliorino, M. R.
    Niho, S.
    Nakagawa, K.
    Lee, K. H.
    Corral, J.
    Rosell, R.
    Linke, R.
    Tang, Y.
    Pastel, M.
    Wilner, K.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S617 - S618
  • [7] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    ONCOTARGET, 2017, 8 (43) : 75712 - 75726
  • [8] Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
    Zhang, Longfeng
    Li, Na
    Liu, Maobai
    Zheng, Bin
    Wu, Zhijuan
    Cai, Hongfu
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4263 - 4270
  • [9] Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Cortijo, Julio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (04) : 325 - 335
  • [10] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
    Liam, Chong-Kin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S62 - S66
12345